We are a contract manufacturing organization (CMO) with a capacity to produce biological active pharmaceutical ingredients at a lower cost, higher purity and guaranteed stability
We perform on-going research in order to identify new alkaloids targeting breast and stomach cancer immunotherpay
Active Pharmaceutical Ingedients
Lappaconitine - purity > 98%
Lappaconitine hydrobromide - purity > 98%
Vincristine - purity > 98%
Vinblastine - purity > 98%
Our technology aims to produce individual alkaloids from clients’ raw material, perform post-treatment of alkaloid mixtures, and separate high purity individual substances required by our clients. We can also produce concentrated extracts using an extractant requested by our clients.
A group of scientists working with alkaloids extraction for decades was able to solve three issues: lowering the price of life-saving compounds such as vincristine*, decreasing the footprint and fixing compounds' stability.
Our goal is to deliver best in class quality and purity for the lowest price and develop new alkaloid-based solutions such as aaptamine* and rhynchophylline*.
*aaptamine: antimicrobial and/or cancer-fighting properties
*rhynchophylline: known neuroprotective alkaloid; an inhibitor of EphA4, a novel target for Alzheimer Disease, a drug candidate for several cardiovascular and central nervous system diseases
RESEARCH AND DEVELOPMENT:
Uncaria species (Gouteng in Chinese) have been used as ethnopharmacological medicines to treat ailments of the cardiovascular and central nervous systems. As the main alkaloid constituent of Uncaria species, rhynchophylline has drawn extensive attention in recent years for its antihypertensive and neuroprotective activities, and its pharmacological effects are related to ethnopharmacological medicine properties of Uncaria species.
As is a candidate drug for several cardiovascular and central nervous system diseases, rhynchophylline will attract scientists to pursue the potential pharmacological effects and mechanisms with new technologies.
Due to the low concentration of rhynchophylline in Uncaria species and therefore the signifincant footprint, only a few clinical studies were conducted. Thus, more in vivo validations and investigations of antihypertensive and neuroprotective mechanisms of rhynchophylline are necessary. We were able to reduce the footprint and remain the nature almost untouched with patent claimed extraction process, therefore we are able to provide more material for clinical studies, as well as offer rhynchophylline as an active pharmaceutical ingredient.
Aaptamine (1), isoaaptamine (2), and demethylaaptamine (3) were isolated from the marine sponge Aaptossuberitoides collected in Indonesia as inhibitors of the proteasome. They inhibited the chymotrypsin-like and caspase-like activities of the proteasome with IC50 values of 1.6–4.6 μg/mL, while they showed less inhibition of the trypsin-like activity of the proteasome. The three compounds showed cytotoxic activities against HeLa cells, but their cytotoxicity did not correlate with their potency as proteasome inhibitors, strongly suggesting that their proteasomal inhibitory activity is dispensable to their cytotoxicity.
Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer
At the inhibitory concentration (IC50), aaptamine exerted an antiproliferative effect, whereas demethyloxyaaptamine and isoaaptamine were strong inducers of apoptosis. The analysis of changes in the proteome of NT2-R cells treated with these compounds. 16-22 proteins were found to be significantly altered, of which several were validated by Western blotting and two-dimensional Western blotting analysis. Changes in the proteome pattern frequently resulted from post-transcriptional protein modifications, i.e. phosphorylation or hypusination in the case of eIF5A. Although the lists of altered proteins were heterogeneous and compound-specific, gene ontology analyses identified rather similar profiles regarding the affected molecular functions. Ingenuity pathway analysis by IPA put the following factors in a central position of the hypothetical networks: myc and p53 for aaptamine; tumor necrosis factor (TNF) for demethyloxyaaptamine; and all three, myc, p53, and TNF for isoaaptamine.